<DOC>
	<DOCNO>NCT02422563</DOCNO>
	<brief_summary>Randomized comparison neoadjuvant chemotherapy follow radical hysterectomy pelvic Â± para-aortic lymphonodectomy ( LNE ) versus primary cisplatin-based chemo-radiation patient cervical cancer FIGO IB2 IIB .</brief_summary>
	<brief_title>NeoAdjuvant Chemotherapy Followed Radical Hysterectomy ( OP ) Versus Primary Chemo-RADiation Cervical Cancer FIGO Stage IB2 IIB</brief_title>
	<detailed_description>The optimal treatment patient cervical cancer FIGO stage IB2 IIB controversial . There randomized comparison dose-dense NACT ( TP TIP-schedule ) follow hysterectomy LNE ( investigational Arm A ) versus primary chemo-radiation ( standard arm B ) . Primary endpoint DFS 5 year , secondary endpoint local control 5 year , OS 5 year , QOL , questionnaires sexual activity/QOL .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>&gt; 18 year cervical cancer FIGO IB2 , IIB , squamous cell , adeno adenosquamous cell carcinoma inform consent small cell/neuroendocrine component previous radiation , previous cancer pregnancy HIV severe comorbidities</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>FIGO IB2 , FIGO IIB</keyword>
	<keyword>chemo-radiation</keyword>
	<keyword>dose dense chemotherapy</keyword>
	<keyword>cisplatin</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>carboplatin</keyword>
	<keyword>ifosfamide</keyword>
</DOC>